S D
-
Technology gains renewing interest in needle arrays as drug delivery devices
Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered.
S D | 12 April 2012
-
GEA Pharma Systems develops inline moisture sensor
GEA Pharma Systems, in co-operation with NDC, has developed an inline moisture sensor for pharmaceutical drying systems.
S D | 26 March 2012
-
GEA Pharma appoints director of sales, business development for Latin America
GEA Pharma Systems has appointed Zósimo López Moreno as its director sales and business development for Latin America.
S D | 22 March 2012
-
Agilent Technologies introduces DNA methylation target-enrichment system
Agilent Technologies expanded its target-enrichment platform with the SureSelect XT Human Methyl-Seq system for epigenetic research into DNA methylation sites. It is the first comprehensive DNA methylation discovery system using target enrichment.
S D | 27 February 2012
-
Vietnam: Boosting its domestic pharmaceutical industry
Rising presence of health issues such as gastrointestinal problems in the country is creating a huge demand for drugs.
S D | 27 January 2012
-
US government HIV/AIDS clinical trial sites to accelerate completion of Phase III TB drug trial
The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases’ (NIAID) AIDS Clinical Trial Group (ACTG) to conduct and help complete a Phase III clinical trial testing potentially faster-acting tuberculosis (TB) treatments.
S D | 09 January 2012
-
Phosphagenics licenses Diclofenac gel for Indian market
Phosphagenics has licensed TPM/diclofenac, its topical non-steroidal pain formulation, to Themis Medicare of Mumbai for the Indian market. This represents Phosphagenics’ first commercial deal in India and its first licensing agreement of its diclofenac product. Under the terms of the agreement, Themis Medicare is committed to pay Phosphagenics an undisclosed up-front fee and double-digit royalty payments on sales.
S D | 06 January 2012
-
ICON Development Solutions appoints general manager of Asia Pacific
ICON announced that its development solutions division has appointed Dr Daniel Tang as general manager, Asia Pacific. Dr Tang will lead the development of ICON’s early phase activities across the region, including bioanalytical laboratory services, and the development of strong links with key opinion leaders for early phase clinical testing.
S D | 12 December 2011
-
Vorapaxar’s data presented at AHA, published in NEJM
Researchers presented and published results from TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist from Merck (known as MSD outside the US and Canada).
S D | 18 November 2011
-
Sanofi appoints David Meeker Chief Executive Officer of Genzyme
Christopher A Viehbacher will retain the position of Chairman, Genzyme.
S D | 24 October 2011
